Ask AI
ASH 2025 Nonmalignant Hematologic Disorders

CE / CME

Emerging Data and Clinical Implications in Nonmalignant Hematologic Disorders: ASH 2025 Highlights

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 20, 2026

Expiration: August 19, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this text-based module, Hanny Al-Samkari, MD, and Joseph J. Shatzel, MD, MCR, discuss key findings in nonmalignant hematologic disorders presented at the 2025 American Society of Hematology (ASH) Annual Meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.  

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with nonmalignant hematologic disorders do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

In the phase III VAYHIT2 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who had received prior corticosteroids but no second‑line therapy, which statement best reflects a key finding compared with the control arm of placebo plus eltrombopag?

A 68‑year‑old hospitalized patient with pneumonia and iron deficiency anemia (IDA) has ongoing fatigue, hemoglobin 8.9 g/dL, and rising transfusion needs. The team is unsure whether IV iron is safe during infection. Based on a large real‑world study of IV iron use in IDA with acute infection that was reported at ASH 2025, what is the best management approach?

In the VIVID 3 study, VGA039 showed preliminary promise as a potential prophylactic therapy for which group of patients?

Based on VAYHIT3 findings reported at ASH 2025, what would you tell a patient with previously treated ITP about how ianalumab monotherapy may affect their protection from infections such as the flu due to their previous vaccinations?